Related Experiment Video
Updated: May 26, 2025
06:18
Assessing the Autonomic and Behavioral Effects of Passive Motion in Rats using Elevator Vertical Motion and Ferris-Wheel Rotation
Published on: February 7, 2020
6.7K
Choosing a drug to treat motion sickness
Gayle B Bodner1, Courtney J Perry
1Gayle B. Bodner and Courtney J. Perry are assistant professors in the PA program at Wake Forest University School of Medicine in Winston-Salem, N.C. The authors have disclosed no potential conflicts of interest, financial or otherwise.
JAAPA : Official Journal of the American Academy of Physician Assistants
|February 25, 2025
Summary
For persistent motion sickness, individualized drug therapy may be recommended. Prophylactic treatment with antihistamines or scopolamine can help manage refractory symptoms.
Area of Science:
- Pharmacology
- Neuroscience
- Clinical Medicine
Background:
- Motion sickness affects many individuals, impacting quality of life.
- Standard behavioral modifications and trigger avoidance are not always effective.
- Refractory cases require targeted therapeutic strategies.
Purpose of the Study:
- To explore pharmacologic interventions for motion sickness.
- To provide recommendations for individualized treatment plans.
- To identify effective prophylactic drug therapies for refractory motion sickness.
Main Methods:
- Review of existing literature on motion sickness pharmacotherapy.
- Analysis of clinical data on antihistamine and scopolamine efficacy.
- Evaluation of individualized treatment approaches.
Main Results:
- Pharmacologic therapy can be beneficial for patients with persistent motion sickness.
- Individualized recommendations are key for optimizing treatment outcomes.
- First-generation antihistamines and scopolamine show efficacy in prophylactic management.
Conclusions:
- Patients with refractory motion sickness can benefit from drug therapy.
- Tailored pharmacologic recommendations improve management of motion sickness.
- Prophylactic use of specific medications offers a viable solution for difficult cases.
Related Concept Videos
01:15Equilibrium and Balance
4.3K
The inner ear assumes dual functionalities of auditory perception and equilibrium maintenance. The vestibule is the organ responsible for balance. This organ contains mechanoreceptors, specifically hair cells, endowed with stereocilia, which aid in deciphering information regarding the position and motion of our heads. Two intrinsic components, the utricle and saccule, help perceive head position, while the semicircular canals track head movement. Neurological messages initiated in the...
4.3K
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
211
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
211
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
172
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
172
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
233
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
233
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
202
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
202
01:22Pathophysiology of Vomiting
278
Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through...
278